Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Personalis, Inc. (NASDAQ: PSNL) had its price target lowered by analysts at HC Wainwright from $11.00 to $8.00. They now have a "buy" rating on the stock.
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
Personalis, Inc. (NASDAQ: PSNL) had its price target raised by analysts at Lake Street Capital from $7.00 to $9.00. They now have a "buy" rating on the stock.